Indications |
Ophthalmic Mydriasis and cycloplegia for diagnosis Adult: As hydrochloride: Instill 1 drop of a 0.5% solution into the affected eye/s repeated after 5-15 minutes. Deeply pigmented eyes are more resistant to pupillary dilatation and may require the use of 1% solution. Child: Instill 1-2 drops of a 1% solution repeated after 5-15 minutes. Infants ≤3 mth: Not recommended. Ophthalmic Uveitis Adult: As hydrochloride: Instill 1-2 drops of a 0.5% soln up to 4 times daily into the affected eye/s. Ophthalmic Iritis Adult: As hydrochloride: Instill 1-2 drops of a 0.5% soln up to 4 times daily into the affected eye/s. |
Contraindications |
Narrow-angle glaucoma. |
Warnings / Precautions |
Intraocular pressure. May impair ability to drive for 1-2 hrs after mydriasis. Childn, elderly. Pregnancy, lactation. |
Adverse Reactions |
Local irritation, hyperaemia, oedema and conjunctivitis, increased IOP (may precipitate narrow-angle glaucoma), systemic anticholinergic effects, severe CNS disturbances in child (rare). |
Overdose Reactions |
Physical weakness, nausea, lightheadedness, changes in emotional state, unprovoked weeping, loss of equilibrium and tachycardia. Spontaneous recovery occurred within 1 hr to several days. |
Mechanism of Actions |
Cyclopentolate is an anticholinergic. It produces dilatation of the pupil and paralysis of accommodation. Has a shorter duration of action than atropine. |
Storage Conditions |
Ophthalmic: Store at 15-25°C. |
ATC Classification |
S01FA04 - cyclopentolate ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics. |
Storage |
Ophthalmic: Store at 15-25°C. |
Available As |
|
Cyclopentolate
Post Review about Cyclopentolate Click here to cancel reply.
Cyclopentolate Containing Brands
Cyclopentolate is used in following diseases
Drug - Drug Interactions of Cyclopentolate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.